...
首页> 外文期刊>Seminars in Nephrology >Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up.
【24h】

Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up.

机译:糖尿病肾病和转化生长因子-β:改变了我们对肾小球硬化和纤维化的看法。

获取原文
获取原文并翻译 | 示例
           

摘要

The manifestations of diabetic nephropathy may be a consequence of the actions of certain cytokines and growth factors. Prominent among these is transforming growth factor beta (TGF-beta) because it promotes renal cell hypertrophy and stimulates extracellular matrix accumulation, the 2 hallmarks of diabetic renal disease. In tissue culture studies, cellular hypertrophy and matrix production are stimulated by high glucose concentrations in the culture media. High glucose, in turn, appears to act through the TGF-beta system because high glucose increases TGF-beta expression, and the hypertrophic and matrix-stimulatory effects of high glucose are prevented by anti-TGF-beta therapy. In experimental diabetes mellitus, several reports describe overexpression of TGF-beta or TGF-beta type II receptor in the glomerular and tubulointerstitial compartments. As might be expected, the intrarenal TGF-beta system is triggered, evidenced by activity of the downstream Smad signaling pathway. Treatment of diabetic animals with a neutralizing anti-TGF-beta antibody prevents the development of mesangial matrix expansion and the progressive decline in renal function. This antibody therapy also reverses the established lesions of diabetic glomerulopathy. Finally, the renal TGF-beta system is significantly up-regulated in human diabetic nephropathy. Although the kidney of a nondiabetic subject extracts TGF-beta1 from the blood, the kidney of a diabetic patient actually elaborates TGF-beta1 protein into the circulation. Along the same line, an increased level of TGF-beta in the urine is associated with worse clinical outcomes. In concert with TGF-beta, other metabolic mediators such as connective tissue growth factor and reactive oxygen species promote the accumulation of excess matrix. This fibrotic build-up also occurs in the tubulointerstitium, probably as the result of heightened TGF-beta activity that stimulates tubular epithelial and interstitial fibroblast cells to overproduce matrix. The data presented here strongly support the consensus that the TGF-beta system mediates the renal hypertrophy, glomerulosclerosis, and tubulointerstitial fibrosis of diabetic kidney disease.
机译:糖尿病性肾病的表现可能是某些细胞因子和生长因子的作用的结果。其中最突出的是转化生长因子β(TGF-beta),因为它促进了肾细胞肥大并刺激了细胞外基质的积累,这是糖尿病性肾脏疾病的两个标志。在组织培养研究中,培养基中高浓度的葡萄糖会刺激细胞肥大和基质产生。反过来,高葡萄糖似乎通过TGF-β系统起作用,因为高葡萄糖会增加TGF-β的表达,并且高糖的肥大性和基质刺激作用可通过抗TGF-β疗法预防。在实验性糖尿病中,有几篇报道描述了肾小球和肾小管间质区室中TGF-β或TGF-βII型受体的过表达。如预期的那样,肾内TGF-β系统被触发,由下游Smad信号传导途径的活性证明。用中和性抗TGF-β抗体治疗糖尿病动物可防止肾小球系膜基质扩张和肾功能逐渐下降。这种抗体疗法还可以逆转已建立的糖尿病肾小球病变。最后,在人类糖尿病性肾病中,肾脏TGF-β系统明显上调。尽管非糖尿病受试者的肾脏从血液中提取TGF-beta1,但糖尿病患者的肾脏实际上将TGF-beta1蛋白精制到了循环系统中。同样,尿液中TGF-β的水平升高与临床预后差有关。与TGF-β协同作用,其他代谢介质(例如结缔组织生长因子和活性氧)促进了过量基质的积累。这种纤维化的积累也发生在肾小管间质中,这可能是由于TGF-β活性增强,刺激了肾小管上皮细胞和间质成纤维细胞过度产生基质。本文提供的数据强烈支持TGF-β系统介导糖尿病性肾脏疾病的肾脏肥大,肾小球硬化和肾小管间质纤维化的共识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号